Intracavitary therapies for upper tract urothelial carcinoma

References

• Soria F, Shariat SF, Lerner SP, et al. Epidemiology, diagnosis, preoperative evaluation and prognostic assessment of upper-tract urothelial carcinoma (UTUC). World J Urol. 2017 Mar;35(3):379–387. PubMed PMID: 27604375; eng.
   PubMed Web of Science ®Google Scholar
• Roupret M, Babjuk M, Comperat E, et al. European Association of Urology Guidelines on upper urinary tract urothelial carcinoma: 2017 update. Eur Urol. 2018 Jan;73(1):111–122. PubMed PMID: 28867446; eng.
   PubMed Web of Science ®Google Scholar
• Goel MC, Mahendra V, Roberts JG. Percutaneous management of renal pelvic urothelial tumors: long-term follow up. J Urol. 2003 Mar;169(3):925–9; discussion 929–30. PubMed PMID: 12576814; eng
   Web of Science ®Google Scholar
• Elliott DS, Blute ML, Patterson DE, et al. Long-term follow-up of endoscopically treated upper urinary tract transitional cell carcinoma. Urology. 1996 Jun;47(6):819–825. PubMed PMID: 8677570.
   PubMed Web of Science ®Google Scholar
• Keeley FX Jr., Bagley DH. Adjuvant Mitomycin C following endoscopic treatment of upper tract transitional cell carcinoma. J Urol. 1997 Dec;158(6):2074–2077. PubMed PMID: 9366315; eng.
   PubMed Web of Science ®Google Scholar
• Palou J, Piovesan LF, Huguet J, et al. Percutaneous nephroscopic management of upper urinary tract transitional cell carcinoma: recurrence and long-term follow up. J Urol. 2004 Jul;172(1):66–69. PubMed PMID: 15201739; eng.
   PubMed Web of Science ®Google Scholar
• Martinez-Pineiro JA, Garcia Matres MJ, Martinez-Pineiro L. Endourological treatment of upper tract urothelial carcinomas: analysis of a series of 59 tumors. J Urol. 1996 Aug;156(2 Pt 1):377–385. PubMed PMID: 8683683; eng
   PubMed Web of Science ®Google Scholar
• See WA. Continuous antegrade infusion of adriamycin as adjuvant therapy for upper tract urothelial malignancies. Urology. 2000 Aug 1;56(2):216–222. PubMed PMID: 10925081; eng
   PubMed Web of Science ®Google Scholar
• Katz MH, Lee MW, Gupta M. Setting a new standard for topical therapy of upper-tract transitional-cell carcinoma: BCG and interferon-alpha2B. J Endourology. 2007 Apr;21(4):374–7; discussion 377. PubMed PMID: 17451325; eng
   PubMed Web of Science ®Google Scholar
• Yossepowitch O, Lifshitz DA, Dekel Y, et al. Assessment of vesicoureteral reflux in patients with self-retaining ureteral stents: implications for upper urinary tract instillation. J Urol. 2005 Mar;173(3):890–893. PubMed PMID: 15711312; eng.
   PubMed Web of Science ®Google Scholar
• Patel A, Fuchs GJ. New techniques for the administration of topical adjuvant therapy after endoscopic ablation of upper urinary tract transitional cell carcinoma. J Urol. 1998 Jan;159(1):71–75. PubMed PMID: 9400440; eng
   PubMed Web of Science ®Google Scholar
• Rastinehad AR, Smith AD. Bacillus Calmette-Guerin for upper tract urothelial cancer: is there a role? J Endourology. 2009 Apr;23(4):563–568. PubMed PMID: 19335155; eng
   PubMed Web of Science ®Google Scholar
• Thalmann GN, Markwalder R, Walter B, et al. Long-term experience with bacillus Calmette-Guerin therapy of upper urinary tract transitional cell carcinoma in patients not eligible for surgery. J Urol. 2002 Oct;168(4 Pt 1):1381–1385. PubMed PMID: 12352398; eng
   PubMed Web of Science ®Google Scholar
• Pollard ME, Levinson AW, Shapiro EY, et al. Comparison of 3 upper tract anticarcinogenic agent delivery techniques in an ex vivo porcine model. Urology. 2013 Dec;82(6):1451.e1-6. PubMed PMID: 24139525; eng.
   PubMed Web of Science ®Google Scholar
• Liu Z, Ng J, Yuwono A, et al. Which is best method for instillation of topical therapy to the upper urinary tract? An in vivo porcine study to evaluate three delivery methods. Int Braz J Urol. 2017 Nov-Dec;43(6):1084–1091. PubMed PMID: 29039888; PubMed Central PMCID: PMCPMC5734071. eng.
   PubMed Web of Science ®Google Scholar
• Yokogi H, Wada Y, Mizutani M, et al. Bacillus Calmette-Guerin perfusion therapy for carcinoma in situ of the upper urinary tract. Br J Urol. 1996 May;77(5):676–679. PubMed PMID: 8689109; eng
   PubMedGoogle Scholar
• Nonomura N, Ono Y, Nozawa M, et al. Bacillus Calmette-Guerin perfusion therapy for the treatment of transitional cell carcinoma in situ of the upper urinary tract. Eur Urol. 2000 Dec;38(6):701–4;discussion 705. PubMed PMID: 11111187; eng
   PubMed Web of Science ®Google Scholar
• Irie A, Iwamura M, Kadowaki K, et al. Intravesical instillation of bacille Calmette-Guerin for carcinoma in situ of the urothelium involving the upper urinary tract using vesicoureteral reflux created by a double-pigtail catheter. Urology. 2002 Jan;59(1):53–57. PubMed PMID: 11796281; eng
   PubMed Web of Science ®Google Scholar
• Okubo K, Ichioka K, Terada N, et al. Intrarenal bacillus Calmette-Guerin therapy for carcinoma in situ of the upper urinary tract: long-term follow-up and natural course in cases of failure. BJU Int. 2001 Sep;88(4):343–347. PubMed PMID: 11564018; eng
   PubMed Web of Science ®Google Scholar
• Miyake H, Eto H, Hara S, et al. Clinical outcome of bacillus Calmette-Guerin perfusion therapy for carcinoma in situ of the upper urinary tract. Int Jl Urol. 2002 Dec;9(12):677–680. PubMed PMID: 12492951; eng
   PubMed Web of Science ®Google Scholar
• Hayashida Y, Nomata K, Noguchi M, et al. Long-term effects of bacille Calmette-Guerin perfusion therapy for treatment of transitional cell carcinoma in situ of upper urinary tract. Urology. 2004 Jun;63(6):1084–1088. PubMed PMID: 15183955; eng.
   PubMed Web of Science ®Google Scholar
• Giannarini G, Kessler TM, Birkhauser FD, et al. Antegrade perfusion with bacillus Calmette-Guerin in patients with non-muscle-invasive urothelial carcinoma of the upper urinary tract: who may benefit? Eur Urol. 2011 Nov;60(5):955–960. PubMed PMID: 21807456; eng.
   PubMed Web of Science ®Google Scholar
• Kojima Y, Tozawa K, Kawai N, et al. Long-term outcome of upper urinary tract carcinoma in situ: effectiveness of nephroureterectomy versus bacillus Calmette-Guerin therapy. Int Jl Urol. 2006 Apr;13(4):340–344. PubMed PMID: 16734847; eng.
   PubMed Web of Science ®Google Scholar
• Nishino Y, Yamamoto N, Komeda H, et al. Bacillus Calmette-Guerin instillation treatment for carcinoma in situ of the upper urinary tract. BJU Int. 2000 May;85(7):799–801. PubMed PMID: 10792155; eng
   PubMed Web of Science ®Google Scholar
• Sharpe JR, Duffy G, Chin JL. Intrarenal bacillus Calmette-Guerin therapy for upper urinary tract carcinoma in situ. J Urol. 1993 Mar;149(3):457–9; discussion 459–60. PubMed PMID: 8437246; eng
   PubMed Web of Science ®Google Scholar
• Schoenberg MP, Van Arsdalen KN, Wein AJ. The management of transitional cell carcinoma in solitary renal units. J Urol. 1991 Sep;146(3):700–2; discussion 702–3. PubMed PMID: 1875476; eng
   PubMed Web of Science ®Google Scholar
• Clark PE, Streem SB, Geisinger MA. 13-year experience with percutaneous management of upper tract transitional cell carcinoma. J Urol. 1999 Mar;161(3):772–5; discussion 775–6. PubMed PMID: 10022682; eng
   PubMed Web of Science ®Google Scholar
• Vasavada SP, Streem SB, Novick AC. Definitive tumor resection and percutaneous bacille Calmette-Guerin for management of renal pelvic transitional cell carcinoma in solitary kidneys. Urology. 1995 Mar;45(3):381–386. PubMed PMID: 7879332; eng
   PubMed Web of Science ®Google Scholar
• Rastinehad AR, Ost MC, Vanderbrink BA, et al. A 20-year experience with percutaneous resection of upper tract transitional carcinoma: is there an oncologic benefit with adjuvant bacillus Calmette Guerin therapy? Urology. 2009 Jan;73(1):27–31. PubMed PMID: 18929398; eng.
   PubMed Web of Science ®Google Scholar
• Jabbour ME, Smith AD. Primary percutaneous approach to upper urinary tract transitional cell carcinoma. Urol Clin North Am. 2000 Nov;27(4):739–750. PubMed PMID: 11098771; eng
   PubMed Web of Science ®Google Scholar
• Chang SS, Boorjian SA, Chou R, et al. Diagnosis and treatment of non-muscle invasive bladder cancer: AUA/SUO guideline. J Urol. 2016 Oct;196(4):1021–1029. PubMed PMID: 27317986; eng.
   PubMed Web of Science ®Google Scholar
• Metcalfe M, Wagenheim G, Xiao L, et al. Induction and maintenance adjuvant Mitomycin C topical therapy for upper tract urothelial carcinoma: tolerability and intermediate term outcomes. J Endourology. 2017 Jul 21. PubMed PMID: 28731777; eng. DOI:10.1089/end.2016.0871
   PubMed Web of Science ®Google Scholar
• Matsui Y, Utsunomiya N, Ichioka K, et al. Risk factors for subsequent development of bladder cancer after primary transitional cell carcinoma of the upper urinary tract. Urology. 2005;65(2):279–283.
   PubMed Web of Science ®Google Scholar
• Huang WW, Huang HY, Liao AC, et al. Primary urothelial carcinoma of the upper tract: important clinicopathological factors predicting bladder recurrence after surgical resection. Pathol Int. 2009;59(9):642–649.
   PubMed Web of Science ®Google Scholar
• O’Brien T, Ray E, Singh R, et al. Prevention of bladder tumours after nephroureterectomy for primary upper urinary tract urothelial carcinoma: a prospective, multicentre, randomised clinical trial of a single postoperative intravesical dose of Mitomycin C (the ODMIT-C Trial). Eur Urol. 2011;60(4):703–710.
   PubMed Web of Science ®Google Scholar
• Takaoka E, Hinotsu S, Joraku A, et al. Pattern of intravesical recurrence after surgical treatment for urothelial cancer of the upper urinary tract: a single institutional retrospective long-term follow-up study. Int Jl Urol. 2010;17(7):623–628.
   PubMed Web of Science ®Google Scholar
• Mullerad M, Russo P, Golijanin D, et al. Bladder cancer as a prognostic factor for upper tract transitional cell carcinoma. J Urol. 2004;172(6 Pt 1):2177–2181.
   PubMed Web of Science ®Google Scholar
• Ito A, Shintaku I, Satoh M, et al. Prospective randomized phase II trial of a single early intravesical instillation of pirarubicin (THP) in the prevention of bladder recurrence after nephroureterectomy for upper urinary tract urothelial carcinoma: the THP Monotherapy Study Group Trial. J Clin Oncol. 2013;31(11):1422–1427.
   PubMed Web of Science ®Google Scholar
• Hall MC, Chang SS, Dalbagni G, et al. Guideline for the management of nonmuscle invasive bladder cancer (Stages Ta, T1, and Tis): 2007 update. J Urol. 2007;178(6):2314–2330.
   PubMed Web of Science ®Google Scholar
• Babjuk M, Oosterlinck W, Sylvester R, et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder. Eur Urol. 2008;54(2):303–314.
   PubMed Web of Science ®Google Scholar
• Wu WJ, Ke HL, Yang YH, et al. Should patients with primary upper urinary tract cancer receive prophylactic intravesical chemotherapy after nephroureterectomy? J Urol. 2010 Jan;183(1):56–61. PubMed PMID: 19913833; eng.
   PubMed Web of Science ®Google Scholar
• Lu DD, Boorjian SA, Raman JD. Intravesical chemotherapy use after radical nephroureterectomy: a national survey of urologic oncologists. Urol Oncol. 2017 Mar;35(3):113.e1-113.e7. PubMed PMID: 27884539; eng
   Web of Science ®Google Scholar
• Marchioni M, Primiceri G, Cindolo L, et al. Impact of diagnostic ureteroscopy on intravesical recurrence in patients undergoing radical nephroureterectomy for upper tract urothelial cancer: a systematic review and meta-analysis. BJU Int. 2017 Jun 16. DOI:10.1111/bju.13935. PubMed PMID: 28621055; eng.
   Web of Science ®Google Scholar
• Barros AA, Browne S, Oliveira C, et al. Drug-eluting biodegradable ureteral stent: new approach for urothelial tumors of upper urinary tract cancer. Int J Pharm. 2016 Nov 20;513(1–2):227–237. PubMed PMID: 27590593; eng.
   PubMedGoogle Scholar
• Liourdi D, Kallidonis P, Kyriazis I, et al. Evaluation of the distribution of paclitaxel by immunohistochemistry and nuclear magnetic resonance spectroscopy after the application of a drug-eluting balloon in the porcine ureter. J Endourology. 2015 May;29(5):580–589. PubMed PMID: 25441059; eng.
   PubMed Web of Science ®Google Scholar
• Donin NM, Duarte S, Lenis AT, et al. Sustained-release formulation of Mitomycin C to the upper urinary tract using a thermosensitive polymer: a preclinical study. Urology. 2017 Jan;99:270–277. PubMed PMID: 27720772; eng.
   PubMed Web of Science ®Google Scholar
• Donin NM, Strauss-Ayali D, Agmon-Gerstein Y, et al. Serial retrograde instillations of sustained release formulation of Mitomycin C to the upper urinary tract of the Yorkshire swine using a thermosensitive polymer: safety and feasibility. Urol Oncol. 2017 May;35(5):272–278. PubMed PMID: 28065395; eng.
   PubMed Web of Science ®Google Scholar